Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations
Sign Up to like & getrecommendations! Published in 2021 at "Leukemia"
DOI: 10.1038/s41375-021-01280-8
Abstract: Chemoimmunotherapy with combined fludarabine, cyclophosphamide and rituximab (FCR) has been an effective treatment for patients with chronic lymphocytic leukemia (CLL). We initiated a phase II trial for previously untreated patients with CLL with mutated IGHV… read more here.
Keywords: mutated ighv; leukemia; fludarabine cyclophosphamide; cll mutated ... See more keywords